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Abstract 1 
 2 
Mitochondrial DNA (mtDNA) mutations cause a wide range of serious diseases with 3 
high transmission risk and maternal inheritance. Tissue heterogeneity of the 4 
heteroplasmy rate (“mutant load”) accounts for the wide phenotypic spectrum 5 
observed in carriers. Owing to the absence of therapy, couples at risk to transmit 6 
such disorders commonly ask for prenatal (PND) or preimplantation diagnosis (PGD). 7 
The lack of data regarding heteroplasmy distribution throughout intra uterine 8 
development however hampers the implementation of such procedures. We tracked 9 
the segregation of the m.3243A>G mutation (MT-TL1 gene) responsible for the 10 
MELAS syndrome in the developing embryo/fetus, using tissues and cells from 8 11 
carrier females, their 38 embryos and 12 fetuses. Mutant mtDNA segregation was 12 
found to be governed by random genetic drift, during oogenesis and somatic tissue 13 
development. The size of the bottleneck operating for m.3243A>G during oogenesis 14 
was shown to be individual-dependent. Comparison with data we achieved for the 15 
m.8993T>G mutation (MT-ATP6 gene), responsible for the NARP/Leigh syndrome, 16 
indicates that these mutations differentially influence mtDNA segregation during 17 
oogenesis, while their impact is similar in developing somatic tissues. These data 18 
have major consequences for PND and PGD procedures in mtDNA inherited 19 
disorders. 20 
 21 
Key words 22 
Mitochondria, mitochondrial DNA, MELAS, NARP, respiratory chain deficiency, 23 
embryo, preimplantation genetic diagnosis 24 
 25 
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 3 
Introduction 1 
 2 
Mitochondrial DNA (mtDNA, Genbank NC_001807.4) disorders are common 3 
diseases with maternal inheritance. Their high clinical variability is explained, at least 4 
in part, by variation of the mutant load (heteroplasmy) among individuals, and also 5 
across organs and tissues within an individual, so that mutant loads will surpass the 6 
tissue specific threshold, leading to the manifestation of symptom (Chinnery et al., 7 
1997; Jeppesen et al., 2006). The usual severity of these diseases, the recurrence 8 
risk, usually high though being difficult to predict at the individual level, in offspring 9 
from heteroplasmic carriers (Chinnery et al., 1998), and the absence of efficient 10 
therapy, commonly result in a request from at-risk couples for prenatal (PND) or 11 
preimplantation diagnosis (PGD). Such procedures are however hampered by the 12 
lack of data regarding mtDNA segregation during embryofetal development. 13 
In this respect, most available data come from animal studies. Dramatic shifts 14 
of mtDNA populations (variant/wild-type mtDNA ratio) between the mother and her 15 
offspring in cattle have suggested that a tight bottleneck might account for such a 16 
rapid segregation (Laipis et al., 1988). One important function of this bottleneck could 17 
be to ensure that new mutations will either be lost or fixed rapidly within individuals, 18 
and thus exposed to selection at the population level (Bergstrom and Pritchard, 1998; 19 
Roze et al., 2005). Studies in mice have identified the bottleneck during oogenesis 20 
(Jenuth et al., 1996), through either a reduction of mtDNA content in primordial germ 21 
cells (PGC, Cree et al., 2008), or selection of a small effective number of segregation 22 
units for mtDNA (Cao et al., 2007; Cao et al., 2009; Wai et al., 2008). There are 23 
however no available data so far regarding mutant mtDNA segregation in somatic 24 
tissues during embryofetal development in animal models. 25 
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 4 
In humans, a small number of studies of primary oocytes carrying mtDNA 1 
deletions (Marchington et al., 1998) or point mutations (Blok et al., 1997; Brown et 2 
al., 2001; Marchington et al., 2010) have suggested that a bottleneck operates during 3 
oogenesis. Random genetic drift appeared as the principal mechanism determining 4 
the level of mutant mtDNA within primary oocytes from a carrier of the most common 5 
mtDNA mutation, m.3243A>G (Brown et al., 2001). This mutation affects the MT-TL1 6 
gene [mitochondrially encoded tRNA leucine 1 (UUA/G), MIM 590050], and is 7 
responsible for the MELAS (Mitochondrial myopathy, encephalopathy, lactic acidosis, 8 
and stroke-like episodes, MIM 540000, Goto et al., 1992) and diabetes-deafness 9 
syndromes (MIM 520000, van den Ouweland et al., 1992; Manouvrier et al., 1995).  10 
It is so far not known whether m.3243A>G segregation is governed by random 11 
drift in somatic tissues during human embryofetogenesis. The few available studies 12 
on m.3243A>G carrier fetuses reported a uniform distribution of mutation load among 13 
different tissues from two heteroplasmic 24 and 25 week-old human fetuses 14 
(Matthews et al., 1994; Cardaioli et al., 2000). Our group found similar mutant loads 15 
in chorionic villi and amniocytes from 3 heteroplasmic fetuses (Bouchet et al., 2006). 16 
All these data suggest that MELAS mutant molecules do not segregate much 17 
between 10 to 25 weeks of gestation.  18 
However, we have so far lacked data on the transmission of m.3243A>G by a 19 
carrier to early embryos, and subsequently no information on segregation of this 20 
mutation throughout the entire period of human embryofetal development has 21 
existed. Thanks to our PGD and PND programs, we collected various tissues and 22 
cells at various stages of development in embryos and fetuses from m.3243A>G 23 
carriers, and investigated local and temporal variation of the mutant load, using a 24 
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 5 
quantification test designed to assess m.3243A>G mutant load at the single cell 1 
level.  2 
Aggregation of our data in early embryos and fetuses, with those from a 3 
primary oocyte study in a m.3243A>G carrier (Brown et al., 2001) indicates that 4 
mtDNA segregation is governed by random genetic drift, in germ- and somatic cell 5 
lines, throughout the entire period of human intra-uterine development. The size of 6 
the bottleneck operating during oogenesis for m.3243A>G is additionally suggested 7 
to vary between individuals. Finally, comparison of the current data with those we 8 
previously reported for another common mtDNA mutation, m.8993T>G (MT-ATP6, 9 
ATP synthase subunit 6 gene, MIM 516060) responsible for the NARP syndrome 10 
(Neuropathy, Ataxia, Retinitis Pigmentosa, MIM 551500; Steffann et al., 2006; 11 
Steffann et al., 2007) indicates that these two mutations differentially influence 12 
mtDNA segregation during oogenesis, while their putative impact on mtDNA 13 
segregation appears quite similar in somatic cells during embryofetal development. 14 
 15 
Patients, Materials and Methods 16 
 17 
Patients 18 
This study was approved by the National Ethics Comittee from l’Agence de 19 
Biomedecine and all couples gave informed consent for DNA analyses in themselves 20 
and their embryos/fetuses. 21 
 PND and/or PGD analyses were carried out in 8 individuals from 7 unrelated 22 
families, heteroplasmic for the MELAS m.3243A>G mutation. The questionable 23 
predictive value of a fetal mutant load for the postnatal outcome was emphasized to 24 
all of the couples. In such situations, counseling necessarily refered to postnatal 25 
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 6 
data, attempting to correlate clinical outcome and mutant load (Chinnery et al., 1997; 1 
Uusimaa et al., 2007; Whittaker et al., 2009), and to our personal experience with 2 
PGD/PND for another mtDNA disorder, ie NARP (Gigarel et al., 2005; Steffann et al., 3 
2006; Steffann et al., 2007) and with PND for MELAS (Bouchet et al., 2006). 4 
Accordingly, we postulated that mutant loads over 60% during prenatal life might be 5 
predictive of a serious disorder, while a mutant load below 30% might hopefully be 6 
associated with absence or low severity of the disease. The most complex situation 7 
was a fetal heteroplasmy value in the intermediate range (30 to 60%), a common 8 
finding for the MELAS m.3243A>G mutation in the post-natal period. There is indeed 9 
no available data correlating intermediate mutant load in the prenatal period with the 10 
postnatal outcome.  11 
Seven of the 8 couples (couples 2 to 8) elected to resort to a conventional 12 
PND approach at first. Couple 1 declined the option of pregnancy termination (TOP), 13 
and thus directly went to PGD, that was also offered to couple 2, who had previously 14 
experienced 2 TOP after PND. Both couples were informed that, at this early 15 
embryonic stage (Day 3), a number of issues remained unsolved, precluding any 16 
conclusive prediction on the pre/postnatal outcome of a carrier embryo. These 17 
couples were offered a PND at 16 gestation weeks (GW) to confirm the PGD result in 18 
case of pregnancy.  19 
 20 
Materials 21 
Postnatal period 22 
Mutant loads from carrier females were assessed from blood, and when available, 23 
urine and oral mucosa samples. Single lymphocytes were isolated from patients 1, 2, 24 
3, 5, and 14 as already described (Gigarel et al., 2005).  25 
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 7 
Early embryos 1 
Patients 1 and 2 were subjected to one and three separate PGD cycles, respectively. 2 
A standard in vitro fertilization protocol was performed and oocytes were collected 3 
and fertilized by intracytoplasmic sperm injection (ICSI). 4 
A total of 38 embryos were analyzed. Twenty-three of these embryos were of 5 
appropriate quality, and were therefore submitted to a 2-blastomere biopsy at post-6 
ICSI day 3 for mutant load assessment, as previously described (Gigarel et al., 7 
2004). Briefly, under control by a binocular microscope, the blastomeres were rinsed 8 
twice in a drop of PBS supplemented with 0.1%polyvinyl alcohol (Sigma Aldrich, 9 
France), using a mouth-controlled, finely pulled glass pipette before being transferred 10 
into a transparent microcentrifuge tube containing 3 µl of lysis buffer (Cui et al., 11 
1989).  A small volume of biopsy medium was used as a PCR negative control for 12 
each embryo in order to detect any contamination by exogenous DNA. In the 15 13 
remaining embryos, assessment of the mutant load was performed on the embryo in 14 
toto. All blastomeres were separately analyzed, when possible (couple 1: embryos 1 15 
to 3, and couple 2: embryo 13). Embryo 10 from couple 2 was cultured up to the 16 
blastocyst stage (Day 5), enabling a trophectoderm biopsy as described elsewhere 17 
(McArthur et al., 2005). The trophectoderm and inner cell mass were analyzed 18 
separately. 19 
 20 
Late embryos and fetuses  21 
Prenatal diagnosis was performed in 12 fetuses from 7 carrier women. Fetus 2c 22 
resulted from embryo 7 and 11 transfer after PGD (patient 2), while the remaining 23 
ones were conceived naturally. Chorionic villi (CV, n=8), amniotic fluids 1 (AF1, n=6), 24 
and 2 (AF2, n=1), were sampled at 10, 14, and 30 weeks of gestation (GW), 25 
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 8 
respectively. Individual fetal cells were isolated from CV and AF samples from 6 1 
fetuses, as already described (Steffann et al., 2007), and analyzed separately, to 2 
investigate the intercellular variation of heteroplasmy. Cord blood was collected from 3 
3 fetuses at birth (fetuses 2c, 3, and 4). Postmortem analyses of various tissues were 4 
carried out in two 12 week-old fetuses (fetuses 2a and 2b) and one 19 week-old fetus 5 
(5b) after TOP, and in a 20 week-old miscarriage product (fetus 7a). Parental 6 
informed consent was obtained for these postmortem analyses. Fetal tissues were 7 
carefully dissected, and small tissue biopsies were analyzed separately. Multiple 8 
samples were taken from two term placentas (fetuses 2c and 3), and two 12GW 9 
placentas (fetuses 2a and 2b).  10 
 11 
Methods 12 
DNA extraction  13 
DNA was extracted from blood and tissues, using the Nucleon Bacc3 kit (Amersham 14 
Biosciences, UK), and a classical phenol extraction method, respectively.  15 
 16 
Quantitative analysis of the m.3243A>G mutant load  17 
MELAS mutant load was quantified using a semi-quantitative fluorescent PCR-HaeIII 18 
restriction test.  19 
Since PCR products analysis using a restriction enzyme is thought to allow the 20 
possibility of errors in mutant load assessments, secondary to heteroduplex 21 
formation during the PCR process (Tanno et al., 1991), we first validated our method 22 
of heteroplasmy assessment using mixing experiments and standard curve analysis. 23 
Wild-type and mutant plasmids were mixed to generate 10 samples, each of them 24 
comprising 106 mtDNA copies, with the m.3243G>A (mutant) target at concentrations 25 
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 9 
ranging from 1 to 100%, which were also used to determine the lowest rate of 1 
mutation detection. Each sample was amplified in triplicate, using both “single cell” 2 
and “tissue” methods, and PCR products were submitted to HaeIII digestion.  3 
We furthermore ascertained the reliability of our test over a wide range of 4 
mtDNA copies, from 102 to 106, encompassing the mtDNA copy number usually 5 
present in isolated cells such as lymphocytes, blastomeres and oocytes. 6 
Single cells and embryos were transferred to 3µl alkaline buffer (Cui et al., 7 
1989) and lysed by 10 min heating at 65°C. PCR amplification was carried out using 8 
the forward primer (5’-TGAGTTCAGACCGGAGTAATC-3’) and the reverse 9 
fluorescent primer (*) (5’-(6-Fam) CTTAACAACATACCCATGGC-3’). Separate 10 
experimental conditions were devised for whole tissue sample and single cell/early 11 
embryo analyses.  12 
Tissue sample DNA (1ng) was amplified in a 30µl reaction volume containing 13 
1.5U Expand Taq DNA Polymerase, 10X PCR buffer 2 (3µl, Roche Diagnostics, 14 
Mannheim, Germany), 0.5µM of each primer (Proligo, Paris, France), and 2mM 15 
dNTP mix (Roche Diagnostics, Germany). Initial denaturation was carried out at 97°C 16 
for 7 min 20s followed by 20 cycles (97°C for 20s, 60°C for 30s, 68°C for 1min 15s) 17 
and final extension of 7 min at 68°C.  18 
For a single cell or embryo analysis, the PCR reaction contained 3 µl of lysis 19 
buffer (lysed cell or negative control), each primer at 0.5µM, master mix 2X (12.5µl, 20 
QIAGEN Multiplex PCR kit, QIAGEN S.A, Courtaboeuf, France), and double-distilled 21 
water up to a 25-µl final volume. PCR programs were 15 min of denaturation at 95°C, 22 
followed by 25, 26, 27, and 30 PCR cycles for whole embryos, trophoblastic cells, 23 
blastomeres, and amniocytes, respectively, consisting of 30s at 94°C, 90s at 60°C 24 
and 60s at 72°C, with a 30-min final extension at 60°C.  25 
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 10 
The resulting 251-bp fluorescent PCR products (1µl) were digested for 3 hours 1 
using 10 units of HaeIII and subsequently submitted to electrophoresis using an 2 
automated genetic analyser ABI3130 (Applied Biosystems). Digestion generated 73-3 
bp and 170-bp fluorescent fragments for the mutant and wild-type species, 4 
respectively. Results were analysed with the Genescan and Genotyper software 5 
(Applied Biosystems). The mutant load was calculated by dividing the mutant peak 6 
area (73bp) by the sum of normal (171bp) and mutant (73bp) peak areas. Cross 7 
hybridization of oligonucleotide primers to nuclear DNA was ruled out by PCR 8 
amplification on mtDNA-less Rho0 cells (Parfait et al., 1998).  9 
 10 
Ascertainment of the fetal origin of the CV/AF cells  11 
The fetal origin of single cells collected from CV, AF1, and AF2, was ascertained by 12 
simultaneous analysis of parental and embryofetal DNA using nuclear (CA)n 13 
microsatellite markers (D6S436, D19S559, D19S559, D16S3395, D6S436, and 14 
DXS1073 for fetus 2a, 5a, 5b, 6, 8, and 12b, respectively), enabling to check for  15 
biparental contribution to the cell genotype, and the absence of fetal cell 16 
contamination by maternal DNA (Gigarel et al., 2004). 17 
Amplification of microsatellites markers in single cells required nested PCR. 18 
The first “outer” PCR enabled simultaneous amplification of the MELAS mutation and 19 
an appropriate microsatellite marker. Briefly, cells were amplified using “single-cell” 20 
PCR conditions described above, as a duplex PCR reaction, using 0.5µM of each 21 
primer. 3µl of the first amplification product were subsequently mixed with 22µl of 22 
“inner” amplification mix, which contained inner fluorescent microsatellite primers at 23 
0.5µM, master mix 2X (12.5µl, QIAGEN Multiplex PCR kit, QIAGEN S.A, 24 
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 11 
Courtaboeuf, France), and double-distilled water up to a 25µl final volume. PCR 1 
program was as described above (20 PCR cycles). 2 
 3 
Statistical analyses 4 
Variance analysis and calculation of inter or intra class correlation coefficients were 5 
used to analyze quantitative traits. Qualitative traits were analyzed using à Chi2 test. 6 
The 95% confidence intervals of the measurements from Patient 2 were made by 7 
fitting a Kimura distribution (Wonnapinji et al., 2008) to the 35 mutation level 8 
measurements from this patient, and then drawing 10,000 simulated sets of 35 9 
measurements from this Kimura distribution to estimate the confidence intervals due 10 
to sample size effects (Wonnapinji et al., 2010). 11 
 12 
Results 13 
 14 
Sensitivity, linearity, and reproducibility of mutant load quantification 15 
Mixing various proportions of wild type and mutant plasmids enabled us to establish 16 
that the measured level of heteroplasmy was a linear function of the expected ratio 17 
(Figure 1). The correlation coefficient for the observed vs expected proportion of 18 
mutant was 0.99 for both “single cell” and “tissue” conditions. Triplicate experiments 19 
yielded to similar results (SD<1.7%), and mutant molecules could be detected in a 20 
proportion as low as 2% of the total mtDNA amount, thus validating reproducibility 21 
and sensitivity of the assay. These results were got with a 106 mtDNA copy number 22 
In order to demonstrate an insensitivity to template input amounts for this particular 23 
method, we ascertained the reliability of our test over a wide range of mtDNA copies, 24 
from 102 to 106. Results are displayed in Supp. Figure S1. 25 
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 1 
Analysis in carrier women  2 
Mutant loads from the 8 carriers applying for MELAS PND/PGD (family 1 to 8, Table 3 
1) ranged from 5 to 40%, 8 to 50%, and 15 to 80%, in leucocytes, oral mucosa cells, 4 
and urinary tract cells, respectively. The lowest and highest values were consistently 5 
found in white blood cells and urinary tract cells, respectively, as expected from 6 
previous reports (Chinnery et al., 1997; Chinnery et al., 1999; Frederiksen et al., 7 
2006; Whittaker et al., 2009).  8 
Mutant load assessment in single lymphocytes from 5 carriers showed large 9 
intercellular variations, ranging from 0 to 81%, 0 to 81%, 0 to 95%, 0 to 21%, and 0 to 10 
100 in patients 1, 2, 3, 5, and 14, respectively. When pooling values from all cells 11 
analyzed for a given individual, average mutant load was very close to that achieved 12 
from the overall lymphocyte extract recovered from a 10ml blood sample.  13 
Comparison of the mean heteroplasmy rate vs one standard deviation of the 14 
heteroplasmy distribution at the single-cell level for each of the five lymphocyte pools 15 
(16.2±8.6%) showed a 0.92 correlation coefficient (p<0.05) with a positive slope 16 
(1.14±0.3) (Table 2 and Supp. Figure S2). 17 
 18 
Analysis in Day 3-Day 5 embryos 19 
Thirty-eight embryos from 2 unrelated heteroplasmic women were analyzed. The 20 
m.3243A>G mutant load was assessed in 31 whole embryos and 70 single 21 
blastomeres (Table 3). Exogenous DNA contamination of the embryonic sample was 22 
never detected in any experiment. 23 
Within the whole cohort of analyzed embryos, six had no detectable mutation 24 
(detection threshold: 2%). Taking into account Patient 2 only (35 embryos), the 25 
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 13 
transmission rate was 83%. None of the embryos were homoplasmic mutant. 1 
Heteroplasmy levels ranged from 5 to 77%, with an apparently homogeneous 2 
dispersion of the mutant rates among embryos. The mutant load value was similar in 3 
all blastomeres derived from a single embryo (n = 2 to 11) with a 6% maximal 4 
interblastomere variability. The intraclass correlation coefficient (ICC) was equal to 5 
0.994, consistent with the high level of agreement of intra-embryo measurements, 6 
and contrasting with the inter-embryo variability. When possible, comparison of 7 
heteroplasmy levels between the whole embryo (collected at Day 5) and two of 8 
his/her blastomeres (collected at Day 3) showed a variation rate <7% in 13/16 9 
embryos, and between 10 and 15% in the remaining ones. 10 
 When considering all embryos from patient 2, the distribution of the mutation 11 
level values was consistent with the distribution predicted from neutral drift theory (p-12 
value of 0.53 by KS test) comparing the data against the null hypothesis of the 13 
Kimura distribution (Wonnapinji et al., 2008). When pooling mutant loads measured 14 
in each embryo from a given woman, mean values were 30±15% and 32±23% for 15 
patients 1 and 2, respectively. Each of these values was close to the mutant load 16 
measured in oral mucosa cell DNA from the corresponding woman (30% and 27% for 17 
patients 1 and 2, respectively). 18 
Embryo 10 from family 2, harbouring a 13% mutant load at Day 3, was 19 
cultured up to the blastocyst stage (Day 5) and separated in 2 parts, namely, the 20 
inner cell mass and the trophectoderm. PCR failed to amplify the inner cell mass 21 
DNA, while the heteroplasmy level of the trophectoderm was consistent with the level 22 
measured in Day 3 blastomeres (15% vs 13%). 23 
 24 
Analysis in fetuses over 10GW  25 
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 14 
Mutant loads were assessed in extraembryonic or embryonic tissues collected 1 
between 10GW to term, in 12 fetuses from 7 carriers (families 2 to 8, Table 4). 2 
One fetus did not carry the mutation in his two tested tissues (amniocytes at 3 
16 GW, and cord blood at birth, fetus 4). As observed in early embryos, no fetus was 4 
homoplasmic for the mutant. The mutation load ranged from 4% to 79% in the 11 5 
carriers. There was no substantial variation in mutant loads assessed at various 6 
stages of pregnancies until birth (Table 4). When excluding data from extra-7 
embryonic tissues (10GW trophoblast or at term placenta), m.3243A>G mutant loads 8 
were identical in all tested tissues from a given fetus [mean±SD: 74.6±0.7% (3 9 
tissues), 42±0.8% (5 tissues), 71±2% (5 tissues), and 78±0.9% (7 tissues) for fetuses 10 
2a, 2b, 5b and 7a, respectively]. When placenta and other tissues were available at 11 
the same term of gestation (3 fetuses), values were similar in two fetuses (74.6 vs 12 
74% and 78 vs 78% for fetus 2a and 7a, respectively), while fetus’ 2b mutant load 13 
was higher in placenta than in other tissues (57±2% vs 42±2%, respectively). Multiple 14 
samples in various parts of placenta, aimed at testing  the mutant load distribution, 15 
did not show any substantial variation in 2, 6, 10, and 18 various loci of fetuses’ 2a, 16 
2b, 2c, and 3 placentas, respectively (Table 4), irrespective of the gestation stage (12 17 
GW or at birth). 18 
Single trophoblastic cells (n=83) and amniocytes (n=64) were isolated from 6 19 
fetuses to investigate the intercellular mutant load variation (Figure 2). Simultaneous 20 
analyses of parents’ and fetal cell DNAs using a polymorphic marker proved the fetal 21 
origin and the absence of contamination by maternal DNA of the analyzed cells (not 22 
shown). Large intercellular variations were found both in trophoblastic cells (range: 7-23 
21%, 6-38%, 23-55%, 23-70%, and 64-100%, for fetuses 5a, 6, 12b, 8, and 2a, 24 
respectively), and amniocytes, either at 14 GW (range : 10-23%, 16-42%, and 52-25 
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 15 
94%, for fetuses 12b, 6 and 5b, respectively), or at 30 GW (range : 9-17% and 5-28% 1 
in fetuses 5a and 12b, respectively). When pooling values from all cells analyzed for 2 
a given cell type in a given fetus, the average mutant loads were very close to those 3 
achieved from overall chorionic villi sampling (CVS) and amniotic fluid sample (AFS ) 4 
mutant loads (variation<10%, Figure 2). 5 
Comparison of the mean heteroplasmy rate vs one standard deviation of the 6 
heteroplasmy distribution at the single-cell level for each of the ten fetal cell pools 7 
(34.3±23%) showed a 0.81 correlation coefficient (p<0.01) with a positive slope 8 
(0.13±0.03) (Table 2 and Supp. Figure S2). 9 
 10 
Predictive value of a prenatal mutant load for the postnatal outcome 11 
Assessment of the predictive value of a prenatal mutant load for the disease severity 12 
in the postnatal period is of crucial importance. A follow-up of our small cohort of 13 
patients born after PGD (n=1) or PND (n=9) provided a preliminary indication, even 14 
though for ethical reasons we could not check for the presence of the mutation in 15 
these asymptomatic children. All these children, harbouring mutant loads between 0 16 
and 35% in prenatal period, are indeed healthy at 1 month to 5 years of age (Table 17 
4).  18 
 19 
Discussion 20 
 21 
Analysis of tissues and cells from human embryos and fetuses is currently the only 22 
approach to get some insight into processes that govern maternofetal transmission of 23 
common mtDNA mutations in humans, owing to the numerous technological 24 
difficulties met in attempts at creating animal models of mitochondrial disorders 25 
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 16 
(Inoue et al., 2000; Fan et al., 2008). We used this approach to study the segregation 1 
of m.3243A>G mtDNA molecules during human in utero development, thanks to our 2 
PND/PGD activities, offered to carriers of this mutation. 3 
These data rely on a robust, specific and sensitive assay we devised for the 4 
quantification of the m.3243A>G MELAS mutation in tissues and single cells. 5 
 While last-cycle labeling PCR indeed is a well-established and agreed-upon 6 
standard protocol for the quantification of mtDNA heteroplasmy, a major concern with 7 
this approach is the need to add the labeled primer prior to the last PCR cycle. This 8 
process indeed runs a significant risk of contamination of both the endogenous PCR 9 
product by exogenous DNA, and of the laboratory dedicated to single cell analyses 10 
by the endogenous PCR product. Such a risk, being a minor one when amplifying a 11 
large amount of DNA, becomes a major hurdle to the use of this method, when 12 
applied to single cell analysis.  13 
We ascertained the reliability of our test over a wide range of mtDNA copies, from 14 
102 to 106. This range encompassed the mean value of mtDNA copies in 15 
lymphocytes [around 150 copies, Urata et al 2008; Maagaard et al. 2006] 16 
blastomeres [11 000 – 449 000 copies, Lin et al 2004] and oocytes [200 000 – 17 
800 000 copies, Craven et al. 2010].  Our results demonstrated an insensitivity to 18 
template input amounts for this particular method, thus validating the results of the 19 
experiments carried out on various cells and tissues. 20 
 21 
Analysis in Day 3-Day 5 embryos 22 
To our knowledge, data on the presence of the m.3243A>G mutation at the Day 3 23 
stage of embryonic development have not been reported so far. This mutation was 24 
found in 32 of 38 embryos (84%) from 2 unrelated carriers. This transmission rate is 25 
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 17 
in agreement with a previous report on the presence of m.3243A>G in adult carrier’s 1 
primary oocytes (Brown et al., 2001), whose 74 of 82 oocytes (90%) were 2 
heteroplasmic. A woman carrying the pathogenic mutation may thus have mutation-3 
free embryos, advocating PGD as an appropriate procedure for preventing 4 
recurrence of affected offspring in carriers, at least in the mutant load range reported 5 
in this study.  6 
Mutant DNA molecules were constantly found to be equally distributed among 7 
the various blastomeres of a carrier embryo until Day 5, in agreement with data on 8 
mtDNA polymorphisms achieved in mouse (Dean et al., 2003) and human embryos 9 
(Marchington et al., 2010), as well as on the m.8993T>G (NARP) mutation in human 10 
(Steffann et al., 2006). Single-cell analysis thus reflects the whole embryo mutant 11 
load, supporting relevance of the usual PGD procedure for assessment of the overall 12 
embryo genotypic status. It is however worth noting some occasional variability (up to 13 
15%) in mutant load between single cell measurements and the whole embryo. This 14 
discrepancy could have arisen from either a technical artifact (such as partial loss of 15 
mitochondrion during whole embryo recovery) or physiological distortion in 16 
m.3243A>G segregation from Day 3 (blastomere sampling stage) to Day 5 (whole 17 
embryo recovery stage). This last hypothesis is unlikely since mutant load values 18 
were very close in Day 5 trophectoderm and Day 3 single-blastomeres in the only 19 
embryo where both tissues were available (Table 3), additionally indicating that the 20 
mtDNA molecule segregation is not skewed across embryonic and extraembryonic 21 
cells (trophectoderm) at this developmental stage. Finally, inter blastomere stability of 22 
the mutant load suggests that embryonic heteroplasmy determined from a single cell 23 
analysis provides an accurate estimate of the whole embryo mutant load, as 24 
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 18 
previously reported for other mtDNA variants (Steffann et al., 2006; Craven et al., 1 
2010) 2 
 The m.3243A>G mutant load was found to be highly heterogeneous among 3 
various embryos from a given individual, ranging from 18 to 50% and from 0 to 77% 4 
in patients’ 1 and 2 embryos, respectively. These values on “early” embryos are in 5 
agreement again with those on primary oocytes from a m.3243A>G carrier, the 6 
mutant load of which ranged from 1 to 50% (Brown et al., 2001). Two conclusions 7 
can be derived from these observations.  8 
 The first conclusion concerns the mode of transmission of m.3243A>G from 9 
the mother to her progeny. The distribution of the mutation level values among 10 
Patient 2’s embryos was consistent with the Kimura distribution calculated from the 11 
neutral drift theory. Furthermore, an equal number of her embryos were found to 12 
harbour a mutation level greater than the mean value (18 embryos) and less than the 13 
mean (17 embryos). Finally, the mean level of heteroplasmy amongst all embryos 14 
was very close to the heteroplasmy level seen in the mother (oral mucosal cells and 15 
blood, patients 1 and 2). These data argue for random genetic drift as the 16 
mechanism governing mtDNA segregation during oogenesis. This observation in 17 
humans is in full agreement with the results of a study of heteroplasmy distribution in 18 
the progeny of mice carrying apparently neutral BALB/c and NZB mtDNA sequence 19 
variants (Jenuth et al., 1996). Assuming that blastomere analysis provides a direct 20 
insight on mature oocyte mutant load, our data, gathered with those of Brown et al., 21 
suggest that mtDNA segregation is governed by a random genetic drift mechanism 22 
over the whole oogenesis period.   23 
 The second conclusion regards the size of the bottleneck operating for 24 
m.3243A>G during oogenesis (table 5). The embryos from patient 2 had a larger 25 
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normalized variance (Wonnapinji et al., 2010), and therefore a smaller bottleneck 1 
parameter, than the oocytes from the individual in Brown’s study (Brown et al., 2001). 2 
The confidence intervals did not quite overlap, indicating that there is a real 3 
difference between the bottleneck sizes in these two individuals, though this 4 
difference is not large. These data therefore suggest that some individual-dependent 5 
parameter modulates the bottleneck size for a given mtDNA mutation. 6 
  7 
Analysis in 10 – 37 GW fetuses 8 
Very few data are available on m.3243A>G segregation during fetal development so 9 
far. We looked for this mutation in 12 fetuses from 8 carriers, and aggregated these 10 
data with those that we (patients 12 and 13, Table 4, Bouchet et al., 2006) and other 11 
groups  (patients 9 to 11, Table 4, Matthews et al., 1994; Cardaioli et al., 2000; Chou 12 
et al., 2004)  had previously published. Maternal m.3243A>G was passed on to 17 of 13 
20 fetuses (85% transmission rate). Taking embryonic and fetal data together, 14 
carriers passed on the mutation to 49 of their 58 offspring (84%, Tables 3 and 4). 15 
This transmission risk fits with the MELAS transmission rate calculated from the 16 
mutant load determined in buccal mucosa samples from carriers’ offspring in the 17 
postnatal period (Uusimaa et al., 2007). It can not be ascertained whether the 3 18 
fetuses shown to be mutation-free at 10GW in the current study were mutation-free 19 
embryos initially or alternatively resulted from subsequent loss of mutant mtDNA 20 
molecules they carried at early embryonic stage. All fetuses but one (fetus 2c) were 21 
indeed conceived out of a PGD procedure, and mutant load values at the Day 3 22 
stage were therefore not available. Our data however argue for mutant load stability 23 
throughout the entire period of embryofetal development. In fetus 2c, loads in 14GW 24 
amniocytes and in term cord blood were indeed 4 and 5%, respectively, in agreement 25 
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 20 
with those assessed at early embryonic stage (embryos 7 and 11 from patient 2, 1 
carrying 5 and 14%, respectively, only one of whom, -fetus 2c-, developed). We 2 
similarly did not find any temporal variation of the MELAS mutant load in multiple 3 
samples taken within 10 to 39 GW (Table 4 A and B). 4 
Study of various tissues from six 12-25GW fetuses (2a, 2b, 5b, 7a, 9, 10) 5 
showed a tight intertissue stability in each of them. Mutant load assessed in extra-6 
embryonic (placenta) and embryonic tissues collected at the same gestation term 7 
from 4 fetuses, was found to be similar in 3 of them (2a, 7a, and 9), being higher in 8 
trophoblast (57 vs 42%) from the remaining one (fetus 2b). Discrepancy between 9 
trophoblast and non trophoblastic fetal tissues did not seem to result from an 10 
ascertainment bias secondary to loco-regional mutant load heterogeneity within 11 
placenta, recently shown to exist (Marchington et al., 2006). The heteroplasmy level 12 
was indeed highly similar in six separate regions of fetus 2b placenta (Table 4). Thus, 13 
this placento-fetal discrepancy might be accounted for by selection of a few cells 14 
which will form the first source for the placental membranes in the partitioning 15 
blastocyst. This observation additionally emphasizes that analysis of single CVS 16 
sample, carried out in a PND frame, may fail to assess the fetal mutant load reliably, 17 
as recently reported (Marchington et al., 2010).  18 
The observation of tight mutant load stability, both across tissues and with 19 
time, in all tested fetuses, suggests that mtDNA segregation is mainly governed by 20 
random genetic drift in somatic tissues throughout the entire period of human 21 
embryofetal development. Furthermore, as already noted in embryos, none of the 20 22 
fetuses analyzed so far (Table 4) was found to carry a heteroplasmy rate exceeding 23 
80%, over a wide range of maternal mutant loads (from 5% in WBC to 80% in urinary 24 
tract cells). Whether such a 80 % value has a biological significance (i.e., a 25 
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 21 
hypothetical selection against highly mutated embryos/fetuses) remains speculative. 1 
Since mutations such as m3243A>G exhibit a relatively normal pattern of distribution 2 
around the maternal mean, it would be unlikely, given the relatively small sample size 3 
and the mean maternal mutant load value in majority below 40 % (in blood) in our 4 
series (table 1) to find embryos with greater than 80 % heteroplasmy, even in the 5 
absence of selection.  6 
We attempted to establish at the single cell level the basis of the mutant load 7 
stability observed across fetal tissues. We thus analyzed 147 cells distributed into ten 8 
pools of trophoblastic or amniotic cells (7-30 cells per pool) collected in six unrelated 9 
fetuses within the 10-30 GW period (Figure 2). Except for one homoplasmic mutant 10 
cell (fetus 2a), all cells were heteroplasmic with a mutant load ranging from 5 to 95%. 11 
This observation is in line with the few studies available on MELAS single cells 12 
collected during the postnatal life, that indeed failed to detect mutant loads over 92% 13 
and 98% in lymphocytes (Saitoh et al., 1999) and muscle fibers (Silvestri et al., 14 
2000), respectively. These data argue that, over a critical threshold of heteroplasmy, 15 
the resulting impact on respiratory chain function promotes fetal cell death 16 
(Sasarman et al., 2008). 17 
When pooling values from all cells belonging to a given pool, mutant load 18 
dispersion ranged from 10 to 47% (Figure 2). The frequency distribution of single cell 19 
mutant load within each of the ten cell pools corresponded to a binomial distribution, 20 
with a median value identical or very close to the mean value of heteroplasmy, in 21 
keeping with the random genetic drift mechanism. We subsequently looked for an 22 
optional relationship between a mutation rate at the tissue (chorionic villi or 23 
amniocytes) level and the amplitude of mutant load dispersion at the single cell level 24 
in this tissue (Supp. Figure S2). A previous study using adult carrier lymphocytes had 25 
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 22 
indeed suggested that, the higher the proportion of mutated mtDNA molecules, the 1 
wider the dispersion of heteroplasmy level (Saitoh et al., 1999). Though the number 2 
of single cells analyzed was low in each pool, we however assumed that each of the 3 
ten cell pools was fairly representative of the whole tissue sample, based on mean 4 
mutant load variance consistently less than 10% between the cell pool and the whole 5 
sample. It clearly appeared that, the higher the tissue mutant load, the larger the 6 
heteroplasmy dispersion in trophoblastic and amniotic cells, even if the low number 7 
of analyzed cells precluded any firm conclusion on the biological relevance of this 8 
observation. We then attempted to evaluate whether such a hypothetical relationship 9 
can be considered in various tissues from m.3243A>G carriers, collected in prenatal 10 
and postnatal periods as well. We considered that Saitoh’s study was exposed to 11 
some bias in heteroplasmy assessment, due to the complex experimental procedure 12 
of this study (first PCR, electrophoresis gel extraction of the PCR products, second 13 
PCR, PCR products enzymatic digestion, southern blotting, and bioimager analysis). 14 
Using DNA from five adult carrier females, we therefore recapitulated Saitoh’s study 15 
with our own method of mutant load assessment, in an effort to homogenize our 16 
data. We thus found a statistically significant correlation between the mean mutant 17 
load in each of the five lymphocyte pools and the heteroplasmy distribution at the 18 
single cell level. Interestingly, comparison of our data in lymphocytes and fetal cells 19 
showed a marked difference between curve slopes for a same range of 20 
heteroplasmy, arguing for some tissue-dependence of mtDNA segregation at the cell 21 
level (Supp Figure S2). These data contrast with the few available data of the 22 
literature, regarding single muscle fibers in adult carriers. The latter indeed showed 23 
that, the higher the mean mutant load of a cell pool, the lower the heteroplasmy 24 
distribution at the cell level (Petruzzella et al., 1994; Tokunaga et al;, 1994; Silvestri 25 
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et al., 2000).  However, the range of mutant loads does not overlap between skeletal 1 
muscle (60-100%) and the other tissues (5-60%). Thus, assuming that the apparent 2 
relationship between mean mutant loads at a whole sample level and mutant load 3 
dispersion at the single cell level makes biological sense in all these tissues, it would 4 
remain to be seen whether the proposed tissue-dependance of such correlations is 5 
valid throughout the 0-100% range of heteroplasmy.  6 
 7 
Comparison of prenatal and postnatal data 8 
It is difficult to reconcile the prenatal inter-tissue stability observed in this study, and 9 
the tissue-dependance of m.3243A>G mutant loads in adult carriers, who harbour 10 
heteroplasmy rates almost constantly higher in skeletal muscle, urinary epithelial 11 
tract cells, and hair follicles, than in white blood cells (Chinnery et al., 1999; 12 
Frederiksen et al., 2006; Whittaker et al., 2009).  13 
This tissue dependance has been suggested to result from a replicative 14 
disadvantage of cells harbouring a high mutant load, thus promoting “mutation 15 
epuration” from fast regenerating tissues. Should such a biological process operate 16 
prenatally, it could be missed out within the “short” course of a pregnancy, by 17 
reference to the very slow decrease of mean mutation level in adult white blood cells 18 
(Rajasimha et al., 2008), thus reflecting the apparent inter-tissue mutant load stability 19 
throughout the prenatal period. Alternatively, cell proliferation rate would be identical 20 
among all tissues throughout intra-uterine life, and would become tissue dependant 21 
from a fairly late postnatal period. A similar value of mutant load (65 to 70%) has 22 
indeed been reported in amniocytes at 21 GW, and in peripheral blood and hair 23 
follicles sampled in a four-year old carrier (Chou et al., 2004).  24 
 25 
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Comparison of mtDNA metabolism in m.3243A>G (MELAS) and m.8993T>G 1 
(NARP) mutations throughout human embryofetal development 2 
Comparing mtDNA segregation data throughout human embryofetal development for 3 
two different mtDNA mutations, namely, m.3243A>G/ MELAS and m.8993T>G/ 4 
NARP, highlights striking differences (Figure 3). 5 
While all MELAS embryos herein reported, originating from 20 %-mutant load 6 
carriers, are mutation-free or heteroplasmic up to 75% with an apparently random 7 
distribution of heteroplasmy, the only two reports on m.8993T>G at Day 3-Day 5 8 
embryonic stage indicated that the 3 NARP embryos from a 18-% mutant load carrier 9 
were either wild-type or mutant homoplasmic (Steffann et al., 2006), the 5 remaining 10 
ones carrying low levels of heteroplasmy (4-22%, Tajima et al., 2007). Though the 11 
low number of embryos analyzed so far precludes drawing firm conclusion on a 12 
putative difference of segregation between m.8993T>G and m.3243A>G molecules 13 
during oogenesis, these apparently different patterns of segregation are however 14 
substantiated by the few available analyses of primary oocytes from carriers of these 15 
mutations (Blok et al., 1997; Brown et al., 2001).  A wild-type (1/7) or mutant 16 
homoplasmic state (6/7) was indeed the rule in the 7 NARP primary oocytes from a 17 
50%-mutant load carrier, contrasting with the presence of heteroplasmy in 90% of 82 18 
primary oocytes in a m.3243A>G carrier with a 8 %- mutant load in WBC. It can be 19 
speculated from these data that bottleneck would be of different size between 20 
m.3243A>G and m.8993T>G. 21 
Whether a purifying selection operates in the human germline against 22 
m.8993T>G and m.3243A>G is a matter of debate. Our data in early NARP embryos 23 
(Steffann et al., 2006), those from the analysis of primary oocytes in a m8993T>G 24 
carrier (Blok et al 1997), as well as our previous report on 2 fetuses with a mutant 25 
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load over 85 % from 2 m8993T>G carriers with a 30% mutant load in WBC (Steffann 1 
et al. 2007), clearly argue against such a negative selection for this mutation in 2 
human. As mentioned above, no conclusion can be drawn at this point on the 3 
occurrence of a purifying selection against m.3243A>G in the human germ line, 4 
owing to the limited number of data we achieved, all drawn from low (20 %) mutant 5 
load carriers. It has however to be emphasized that we never observed any fetus 6 
with a mutant load over 80% among the 8 pregnancies from 6 m.3243A>G carriers 7 
with a WBC mutant load equal or even higher than 30 % (patients 6-9, 11, 12, table 8 
1), These data are difficult to reconcile with those from murine germline segregation 9 
studies indicating that mutations in protein coding genes of mtDNA are strongly 10 
selected against, whereas mutations affecting tRNA genes (such as m.3243A>G) are 11 
largely refractory from such a process (Fan et al, 2008, Stewart et al, 2008).  12 
Regarding the somatic tissue development, we previously showed the 13 
existence of fetuses carrying m.8993T>G with various degrees of mutant loads, from 14 
0% to 100 %, over the 10-GW stage of pregnancy until delivery (Steffann et al., 15 
2007). m.8993T>G and m.3243A>G mutant loads remain at a steady-state level with 16 
time or across various tissues, thus supporting a random segregation of mutant 17 
mtDNA molecules throughout somatic embryo-fetogenesis irrespective of the 18 
mutation type.  19 
In conclusion, one can speculate that the bottleneck size, and possibly, the 20 
mutant load threshold critical for embryo/fetus survival, varies among mtDNA 21 
mutations, thus hampering genetic counselling and PND/PGD procedures in 22 
mitochondriopathies resulting from “private” mtDNA mutations. To test this 23 
speculation, we will need to collect data on mtDNA mutant loads for other rarer 24 
mtDNA mutations. 25 
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FIGURES LEGENDS  1 
 2 
Figure 1. Standardization of m.3243A>G load assessment 3 
The rate of m.3243A>G heteroplasmy was assessed by semi-quantitative fluorescent 4 
PCR using 10 samples containing various proportions of mutant plasmid. Each 5 
sample comprised 106 mtDNA copies. Each value is the mean of three independent 6 
experiments. Bars depict standard deviations. WT: wild-type DNA.  7 
 8 
Figure 2. Distribution of m.3243A>G mutation levels across isolated cells 9 
MELAS mutant load was assessed in trophoblastic cells sampled at 10GW (open 10 
boxes) and amniocytes sampled at 14 (hatched boxes) or 30 (filled boxes) GW in 6 11 
fetuses (numbering refers to Table 4). n: number of analyzed cells. Each box depicts 12 
the mean mutant load plus (top bar), and minus 1 standard deviation (bottom bar) 13 
for a given cell pool. Whiskers depict maximal (top) and minimal (bottom) values for 14 
each sample. Central bar: median.      mean mutant load assessed on the whole 15 
chorionic villi, or amniocyte sample. 16 
 17 
Figure 3. Comparative distribution of m.3243A>G and m.8993T>G/C mutant 18 
loads in mature oocytes, blastomeres, and fetal tissues 19 
       m.3243A>G (MELAS syndrome),    m.8993T>G/C (NARP syndrome). Scatter 20 
plots are drawn from personal (black symbols) and literature data (white symbols: 21 
Harding et al.1992;  Matthews et al., 1994; Blok et al., 1997; Ferlin et al., 1997; White 22 
et al., 1999; Cardaioli et al., 2000; Brown et al., 2001; Leshinsky-Silver et al., 2003;  23 
Chou et al., 2004 ; Pettman et al., 2007; Tajima et al., 2007). Each point depicts one 24 
oocyte or one individual (embryo or fetus). All oocyte values were from a single 25 
* 
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carrier of m.3243A>G (Brown et al., 2001) or m.8993T>G (Blok et al., 1997).  When 1 
several values were available for one individual, the average heteroplasmy value was 2 
selected. Both Day 3 and 14GW values were available (and therefore depicted) for 3 
one “NARP” (0% and 0%) and one “MELAS” individual (5% and 5%) only. All other 4 
Day 3-Day 5 and 8-25 GW (gestation weeks) values were from distinct individuals. 5 
 6 
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Supplementary Figure 1. Standardization of m.3243A>G load assessment over 
a 102-105 mtDNA copy range  
The rate of m.3243A>G heteroplasmy was assessed by semi-quantitative fluorescent 
PCR using 5 samples containing various proportions of mutant plasmid (11%, 33%, 
50%, 67%, 89%) and 5 different template amounts (102, 103, 104, 105, 106). Values 
achieved with 106 copies are displayed as Fig 1. Each dot depicts the result of one 
experiment. Y axis: expected percentage of m.3243A>G mutant load. X axis: 
observed percentage of m.3243A>G mutant load.  
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Supplementary Figure 2. Distribution of inter cell dispersion of m.3243A>G 
mutant load according to the heteroplasmy rate of overall cell pools 
Data are represented as standard deviation of the mean mutant load vs mean 
heteroplasmy rate for each pool.     prenatal cell pools: syncitiotrophoblasts and 
amniocytes (data from Table 2 and Figure 2); Black symbols: postnatal cell pools:                          
 lymphocytes (data from Table 2),    muscle fibers (data from Petruzella et al., 
1994; Tokunaga et al., 1994; Silvestri et al., 2000). Each symbol reflects the analysis 
of one cell pool for one individual. 
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Table 1. Maternal m.3243A>G mutant load 
 Patient Mutant load (%) 
  WBC OMC UTC 
A 1 20 30 65 
 2 20 27 30 
 3 20 40 50 
 4 7 8 15 
 5 5 10 35 
 6 30 50 80 
 7 30  70 
 8 40  55 
B 9 39 48  
 10 20   
 11 63   
 12 34 45 80 
 13 21   
A, Patients analyzed in this study. B, Patients reported elsewhere: (9) Matthews et al., 1994, (10) 
Cardaioli et al., 2000 , (11) Chou et al., 2004, (12, 13) our group (Bouchet et al., 2006). WBC, 
white blood cells; OMC, oral mucosa cells; UTC, urinary tract cells. 
 2 
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Table 2.  m.3243A>G mutant load in single cells of various origins 
 Lymphocytes Syncitiotrophoblasts/amniocytes Muscle fibersa 
 Number of patients 5 5 8 
Number of cell pools  5 10 21 
Total cell number 84 147 341 
Heteroplasmy level  
(mean + SD) 
16.2 + 8 % 34.3 + 13 % 78.5 + 17 % 
Correlation 
coefficient (p) 
0.92  (< 0.05) 0.81  (<0.05) 0.84  (<0.01) 
Slope + SD 1.14 + 0.28 0.13 + 0.03 -0.38 + 0.05 
a calculation from data by Tokunaga et al., 1994; Petruzella et al., 1994; Silvestri et al., 2000 
 1
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 Table 3.  m3243A>G mutant load in preimplantation embryos 
   Patient Embryo 
 
Single blastomere 
 
 Overall embryo Median  Mean (±SD) 
  
Blastomere 1 Blastomere 2 
   
1 1   18±1  (n=6)   
 2   23±2  (n=5) 23% 30±15% 
 3   50±3  (n=3)   
           2 1 0a 0    
 2 0 0    
 3 0 0 0   
 4   0   
 5   0   
 6   0   
 7 5 5    
 8 7 8    
 9 12 14    
 10 13 13 Ib     T: 15   
 11 13 16    
 12 17 22 15   
 13 14 15 16±2 (n=11)   
 14 a 25 23   
 15 27 27 23   
 16   28   
 17 15 21 30   
 18 40 41 37 37% 32±23% 
 19   42   
 20   42   
 21   43   
 22   47   
 23 51 55 48   
 24   50   
 25   50   
 26 39 40 50   
 27 54 55 50   
 28   55   
 29   60   
 30 55 55 62   
 31 63 66 63   
 32 51 54 66   
 33 67 68 74   
 34 72 77    
 35 69 71 75   
Patient numbering refers to Table 1. Individual values i) represent the heteroplasmy level of 2 single blastomeres or of embryos in toto, 
ii) are expressed as mean ± SD when more than two blastomeres from one embryo were analyzed (number of analyzed blastomeres 
in brackets). Embryo 10 from family 2 was separated in two parts before PCR analysis, ie, the inner cell mass (I), and the 
trophectoderm (T). Calculation of “overall mean value” and “overall median value” took into account either the mean of the values 
achieved trough analysis of all blastomeres when only blastomeres were available, or values from embryos only in other cases. 
adetection threshold:2%; b PCR failure. 
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Table 4.   m.3243A>G load in extra-embryonic and embryo-fetal tissues 
 Patient Fetus CVS AF1 AF2 Muscle Liver Heart Skin Kidney Lung Gut Brain 
Optic 
nerve 
Thymus 
Umbilical 
cord  
Placenta 
Cord 
blood 
A 2  2a 77±3   75±1.5  74±3.2   74±0      73, 75
a
  
  2b 59±6   42±1  41±2 42±2 43±2 43±0.3      57±2
b
  
  2c  4±0             15±5
c
 5±1 
 3  3 17±3 16±0.5             22±6
d
 16±0 
 4  4  0              0 
 5  5a 20±0.5 15±3 15±2              
  5b  70±1   72±2  73±0 68±2     72±1    
  5c 4±0.6                
 6  6 32±1 28±1               
 7  7a    79±0 78±0.6 77±0.9 78±0.3 79±0 79±0.3     78±1.7 78±1.7  
  7b 79±2                
 8  8 49±0.7                
B 9 9    55±1 52±4 54±3 51±3 56±5  53±4 52±3 51±3   55±3  
 10 10    50 50      50      
 11 11   67              
 12 12a 35 33 29              
  12b 31 23 26              
 13 13a 60 63               
  13b 0 0               
  13c 0 0               
 A, Fetuses analyzed in this study. Chorionic villi (CVS) were sampled at 10 GW, and amniotic fluids (AF) at 14 (AF1) and 30 (AF2) GW, respectively. The 
other tissues were sampled at 12 GW (fetuses 2a and 2b), or at 19, 20, 24, and 25 GW for fetuses 5b, 7, 9, and 10, respectively, and at term for fetuses 2c 
and 3. Cord blood was sampled at birth for fetuses 2c (38GW), 3 (37GW) and 4 (39 GW). All assays were carried out in triplicate. Values are expressed as 
mean ±SD. Placenta values measured on 
a
2, 
b
6, 
c
10, and 
d
18 separate biopsies, respectively (SD: intersample variation). B, Fetuses reported elsewhere: (9) 
Matthews et al., 1995, (10) Cardaioli et al., 2000, (11) Chou et al., 2004, (12, 13) our group (Bouchet et al., 2006). In boldface: patients born after PGD or 
PND. 
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Table 5. Comparative analysis of mutation levels in preimplantation embryos 
from patient 2 and primary oocytes from a published report 
 Patient 2 Brown et al., 2001 
Sample size (n) 35 82 
Mean mutation level (p0) 33.7%   [25.8% – 42.1%] 12.6%   [10% - 15%] 
Mutation level variance (V) 0.06      [0.037 – 0.086] 0.014    [0.009 – 0.020] 
Normalized variance (V/(p0(1-
p0)) 
0.27      [0.18 – 0.38] 0.13      [0.09 – 0.17] 
Bottleneck parameter (b) 0.72       [0.62 – 0.82] 0.87      [0.83 – 0.91] 
Probability of fixing on wild-
type 
8.4%      [1.5% - 19%] 14%      [6% - 24%] 
Probability of fixing on the 
mutant 
0.4%      [0 – 2.0%] 2x10-7   [0 – 1x10-6] 
Probability of having > 60% 
mutant 
17%       [7% - 27%] 0.3%     [0.02% - 0.8%] 
Values are given as mean [95% confidence intervals]. 
The distribution of the mutation level values from Patient 2 was consistent with the Kimura distribution 
(p-value of 0.53 by KS test). 
 
.   
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